Lower Day-to-Day Fasting Self-Measured Plasma Glucose (SMPG) Variability with Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine 100 Units/mL (IGlar U100)
Authors: LINGVAY ILDIKO , DOSHI ANKUR , GARCIA-HERNANDEZ PEDRO A. , MERINO TORRES JUAN FRANCISCO , RODACKI MELANIE , EGGERT SARAH , N RANDI GRØ , JAECKEL ELMAR 
Published: June 2018

Diabetes therapy aims for stable glycemic control and minimal hypoglycemia risk, previously linked to day-to-day variability. In a post-hoc analysis, day-to-day fasting glycemic variability with IDegLira was compared with IGlar U100, in DUAL V (IDegLira vs. IGlar U100) and VII (IDegLira vs. IGlar U100 and bolus insulin aspart) (NCT 01952145 and 02420262). Weekly and overall measures of day-to-day fasting glycemic variability were calculated using subjects’ daily fasting SMPG values, overall measure was used to divide the populations into tertiles, and proportional odds were statistically significant favoring IDegLira (Table). More subjects treated with IDegLira had lower overall day-to-day fasting glucose variability vs. IGlar 100 (Table). Hypoglycemia rates were reduced with lower variability with IDegLira vs. comparators in all tertiles (Table). In DUAL V (IDegLira vs. IGlar U100) and DUAL VII (IDegLira vs. IGlar U100 plus bolus insulin aspart) respectively, statistical analysis of weekly variances showed a 32% (p&lt;0.0001) and 23% (p=0.001) lower day-to-day fasting glycemic variability. Based on fasting SMPG values, there was lower day-to-day variability with IDegLira, possibly contributing to the lower hypoglycemia rate, compared with IGlar U100 in DUAL V and VII.

Disclosure
I. Lingvay: Advisory Panel; Self; Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Intarcia Therapeutics, Inc., Sanofi-Aventis. Research Support; Self; Novo Nordisk A/S, Merck Sharp & Dohme Corp., Pfizer Inc., GI Dynamics Inc., Novartis AG. Other Relationship; Self; Sanofi, AstraZeneca, Boehringer Ingelheim GmbH, Novo Nordisk A/S. A. Doshi: Advisory Panel; Self; Pfizer Inc. P.A. Garcia-Hernandez: Research Support; Self; Novo Nordisk A/S, PAREXEL International Corporation, Amgen Inc., ICON plc.. Speaker's Bureau; Self; Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., AstraZeneca. J. Merino Torres: Advisory Panel; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk A/S. Speaker's Bureau; Self; Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis, Janssen Pharmaceuticals, Inc. M. Rodacki: Research Support; Self; Faperj. Speaker's Bureau; Self; Allergan, Novo Nordisk A/S. Speaker's Bureau; Spouse/Partner; Biogen. S. Eggert: Employee; Self; Novo Nordisk A/S. R. Grøn: Employee; Self; Novo Nordisk A/S. E. Jaeckel: Advisory Panel; Self; Novo Nordisk A/S, Lilly, AstraZeneca, Boehringer, Merck Sharp & Dohme Corp., Janssen, Roche, Novartis. Board Member; Self; Novo Nordisk A/S, Lilly. Research Support; Self; Novo Nordisk A/S, Novartis, Gilead Sciences, Inc., Roche, Miltenyi Biotec, Biotest Pharmaceuticals Corporation, Fresenius SE & Co. KGaA, DFG, BMBF, EU, JDRF, VolkswagenStiftung. Speaker's Bureau; Self; Novo Nordisk A/S, Lilly, AstraZeneca, Boehringer, Merck Sharp & Dohme Corp., Janssen, Roche, Novartis AG.